## Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: L10I • I13V • E35D • M36I • R41K • K45R • L63T • I64IL • H69Q • L89M

| Protease Inhibitors | |
|---|---|
| **atazanavir/r (ATV/r)** | Susceptible |
| **darunavir/r (DRV/r)** | Susceptible |
| **fosamprenavir/r (FPV/r)** | Susceptible |
| **indinavir/r (IDV/r)** | Susceptible |
| **lopinavir/r (LPV/r)** | Susceptible |
| **nelfinavir (NFV)** | Susceptible |
| **saquinavir/r (SQV/r)** | Susceptible |
| **tipranavir/r (TPV/r)** | Susceptible |

**PR comments**

**Other**

- **L10I/V** are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

## Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for PI.*

## Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: K103N • V108I
RT Other Mutations: K20R • V35I • E40ED • V60VI • K122V • S162C • T165I • K173R • Q174K • D177E • I178IL • V179I • T200A • Q207A • R211NS • V245Q • E248ED

| Nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **abacavir (ABC)** | Susceptible |
| **zidovudine (AZT)** | Susceptible |
| **stavudine (D4T)** | Susceptible |
| **didanosine (DDI)** | Susceptible |
| **emtricitabine (FTC)** | Susceptible |
| **lamivudine (3TC)** | Susceptible |
| **tenofovir (TDF)** | Susceptible |

| Non-nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **doravirine (DOR)** | Potential Low-Level Resistance |
| **efavirenz (EFV)** | High-Level Resistance |
| **etravirine (ETR)** | Susceptible |
| **nevirapine (NVP)** | High-Level Resistance |
| **rilpivirine (RPV)** | Susceptible |

**RT comments**

**NNRTI**

- **K103N** is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
- **V108I** is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations.

**Other**

- **V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

## Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for NRTI.*

*Drug resistance mutation scores of NNRTI:* Download CSV

| Rule | DOR | EFV | ETR | NVP | RPV |
|---|---|---|---|---|---|
| V108I | 10 | 10 | 0 | 15 | 0 |
| K103N | 0 | 60 | 0 | 60 | 0 |
| Total | 10 | 70 | 0 | 75 | 0 |